🇺🇸 FDA
Pipeline program

A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

1458-0006

Phase 1 other active

Quick answer

A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity for Obesity is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Obesity
Phase
Phase 1
Modality
other
Status
active

Clinical trials